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The gut-brain axis is becoming a hot topic in the research world for its possible role in many 
disorders and diseases. As we take a deeper dive in to its role in neurodegenerative disorders 
like Parkinson’s disease, we present evidence of a strategy of using genetically engineered 
probiotic to help regulate and maintain levels of L-DOPA, the gold standard of treatment used 
in Parkinson’s disease patients. Evidence from trials with mice and dogs present significant 
findings that prove that a small change like adding a modified E. Coli probiotic may be all the 




Parkinson’s disease (PD) is acknowledged as the second most common neurodegenerative 
disorder, estimated to affect 1-2 people per 1000 of the population worldwide (1). PD is a costly 
neurodegenerative disease that may pose a significant economic burden on patients, the 
healthcare system and society. The chronicity of PD and its lack of treatment make its projected 
economic burden to grow substantially over the next few decades (10), with out-of-pocket 
costs for neurologic medications has increased considerably over the last 12 years (11). The 
total cost of PD is $52 billion every year, with $25.4 billion attributable to direct medical costs 
such as hospitalizations and medication, and $26.5 billion in non-medical costs like missed 
work, lost wages, early forced retirement, and family caregiver time (12).  
To try and alleviate this financial burden, researchers are looking into signs of 
neurodegenerative disease in earlier stages of life. In the last decade, emerging evidence has 
revealed the presence of an intense dialogue between the brain and the GI system, the so-
called gut-brain axis. The microbiota-gut-brain axis has attracted much attention regarding the 
pathogenesis of PD, in which GI dysfunction appears about twenty years before motor 
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impairments. Although PD patients manifest both gut dysmotility and altered microbial 
composition, it is still unclear which condition comes first and what role the gut and the gut 
microbiota have in PD progression (2). L-DOPA has proven to be the most reliable and 
efficacious of the current PD therapeutics for motor deficits in patients with PD. To date, L-
DOPA remains the benchmark therapeutic for the restoration of dopamine in PD (3). L-DOPA is 
not without its negative side effects, however, as increased treatment duration is associated 
with the occurrence of dyskinesia (4). These effects are believed to be caused by the current 
pulsatile delivery of L-DOPA, causing L-DOPA peaks, responsible for the L-DOPA-induced 
dyskinesia, followed by off-periods, responsible for depression and anxiety. There is thus a 
dramatic need for a therapeutic strategy allowing a more constant delivery of L-DOPA. There 
are other options than taking L-DOPA orally to minimize side effects or have stable L-DOPA 
levels. Some options are using drugs like Ondansetron in addition to L-DOPA to reduce L-DOPA 
induced dyskinesia (13) or use entirely new therapies like stereotaxic surgery injecting a drug 
cocktail to alter neurons (14) or doing duodenal levodopa infusions for more stable plasma 
levels and better motor control (15). These alternatives do not treat Parkinson’s side effects as 
well as and/or are much more invasive and expensive than to treat with L-DOPA, meaning that 
L-DOPA is still considered the best treatment course for patients with Parkinson’s disease. 
For that purpose, a probiotic using E. Coli has been genetically engineered to produce L-DOPA 
in a sustained manner (EcNL-DOPA) (5). In order to maximize L-DOPA’s diffusion into the brain, 
we will use Benserazide in combination with EcNL-DOPA. Levodopa is a precursor to the 
neurotransmitter dopamine which is administered to increase its levels in the central nervous 
system.  However, most Levodopa is decarboxylized to dopamine before it reaches the brain, 
and since dopamine cannot cross the blood-brain-barrier, this translates to little therapeutic 
gain with strong peripheral side effects. Benserizide inhibits the aforementioned 
decarboxylation, and since it itself cannot cross the blood-brain barrier, this allows dopamine to 
build up solely in the brain instead (5). By using EcNL-DOPA with Benserizide in both mice and 
dog trials, progress is being made for an effective treatment combating peaks and off-periods 




Animal models are essential in a preclinical study (6) because of their ability to replicate 
symptoms or progression of the disease  for drug development. In order to research, discover 
and understand diseases, test subjects are necessary to figure out what is working and what is 
not. To enable this, reliable animal models are required (7). Despite the need for animal 
models, researchers cannot use animals for research without following strict guidelines from 
the Institutional Animal Care and Use Committee (IACUC). The researchers must ensure the 
humane care and use of animals while interpreting the regulations in a practical, meaningful, 
and reasonable manner that facilitates valuable research and teaching (8). Animal models have 
been used in a large amount of the disease research that has been published, but why use two 
animal models? This is because no single animal is able to mimic a given human disease, which 
is itself polymorphic between patients, but the differences between strains or species provides 
(an) unmatched opportunity to understand disease development and differential host 
response, and eventually fund new cures (9). Each species displays advantages as well as 
disadvantages over the other for showcasing a certain aspect of disease that would further test 
the efficacy of the treatment. Putting the treatment through tests like documenting the 
similarities and differences from one disease species model to another can be the difference of 
the treatment working or not working in a clinical trial. With this in mind, we evaluated L-DOPA 




C57B6 mice and Parkinson’s disease model mice (Mitopark) were divided into 6 groups; C57B6 
treatment group, Mitopark treatment group, C57B6 control group, Mitopark control group, 
C57B6 BZ only group and Mitopark BZ only group. Both treatment groups of mice (C57B6 and 
Mitopark) are treated with a single dose of (2x1010CFU)—suspended in formulating buffer EcN4-
LDOPA-Rham-Re and BZ (40mg/kg Benserazide 100ul). Each of the treatment groups contains 4 
mice that will receive these treatments. The control groups of C57B6 and Mitopark receive no 
treatment and contain 3 mice each. The BZ only groups of C57B6 and Mitopark mice are 
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treated with a single dose of BZ (40mg/kg Benserazide 100ul) with each group containing 4 
mice. Since this trial is done with mice, blood collection is restricted to only 2 blood collections 
per week, hence why multiple mice are used to perform the study and sacrificed at the last 
time point. The mice used were aged 18-20 weeks: 2 males and 2 females for Mitopark and 
C57B6 treatment and BZ groups, 2 males and 1 female for Mitopark control group and 3 
females for C57B6 control group. Baseline urine and blood samples were taken before any 
treatments were given. At each time point during the study, submandibular blood collection in 
EDTA tubes for plasma preparation, 2 tubes of fecal samples  and a urine sample were 
collected. At terminal time points at 4, 8 and 24 hours; blood collection by cardiac puncture for 
plasma preparation and brain dissection were collected and taken. All plasma L-DOPA, BZ and 
urine HVA levels were compared to baseline.  
 
Dog Study 
Dogs spontaneously experience similar symptoms to PD, expressed by depression, anxiety, and 
cognitive dysfunctions, and is thus a very relevant model for this disease (5). Accumulated data 
shows that the dog is the superior model system over mouse models for investigating the 
treatment of neurologic disease because of the environmental, genomic, and intestinal 
physiologic features they share with humans (16) They show a parallel aging process to humans 
as evidenced by beagles between 5-9 years old showing cognitive dysfunction similar to 
humans between 40 and 60 years old (17). Additionally, brain vs body size compares favorable 
between humans and dogs when compared to mice (18). Canine spontaneous disease models 
offer additional predictive value for treatment before transitioning to humans for clinical trials 
(19), along with dogs having being adapted to having a starch-rice diet similar to humans, which 
can improve our understanding of human evolution and disease (20, 21). 
In this study, dogs were given EcNL-DOPA orally for up to 21 days, twice a day. Before 
administration, baseline samples were collected (blood, feces, cerebrospinal fluid [CSF]). During 
the treatment period (up to 21 days), blood and feces were collected again daily. On days 18-
21, CSF was collected again in all dogs. Since this procedure can only be performed on 2-3 dogs 
per day, 4 days were required to complete the CSF taps on all 10 dogs. After CSP taps were 
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performed, the dogs no longer received EcNL-DOPA and entered a wash-out period to make 
sure EcNL-DOPA had indeed been evacuated from the dogs’ system. Unlike EcNL-DOPA, 
Benserizide will continue to be given until the wash out period is completed (up to day 25). The 
reasoning for this is because most Levodopa is decarboxylized to dopamine very quickly in the 
system, it will not be found in the dogs’ system without Benserizide. In order to be sure the 
wash-out is completed, we need to be able to obtain undetectable levels of L-DOPA with 
Benserizide. In addition to all of these measures, twice during the study (once between day -3 – 
day 0 and once between day 1 – day 21) each dogs’ heart rate and ECG will be monitored 
continuously for 24 hours using Holter monitoring. Holter monitoring is a non-invasive 
monitoring system designed to remain on the dog for 24-48 hours without impacting dog’s 
activity in any way. This is to give us additional data to ensure the dog’s wellness and overall 
good health during the study. Feces, after being obtained from spontaneous defecation, was 
sampled on all 10 dogs in order to assess the presence of L-DOPA in the dog’s stools, as well as 
any microbiome changes. Feces was collected once before treatment for baseline values, 
collected as many times as possible during the day during treatment administration and once a 
day in the morning during the wash-out period.  
Blood collection from all 10 dogs followed a specific schedule, which is displayed on Table 1. 
Day -3 to day 0: up to 10mL of blood was collected all at once to run health screening tests 
(CBC, Chemistry) and for baseline values. Day 1 and day 15: up to 3mL of blood was collected at 
up to 10 time points during the day. Each time point was separated by 30 minutes to 2 hours 
and the total blood volume taken on that day did not exceed 30 mL (5% of total blood volume 
in a smaller dog). Day 2 and day 16: up to 3mL of blood was collected at up to 4 time points. 
The time points were separated by 3-4 hours. 3 additional mLs were taken at first time point to 
run CBC/Chemistry and hemocrit. Total blood volume on that day did not exceed 6mL (2.5% of 
total blood volume in a smaller dog). Day 3-14 and day 17: up to 2mL of blood was collected at 
up to 3 time points. The time points were separated by 3-4 hours and the total blood volume 
taken on that day did not exceed 6mL (1% of total blood volume in a smaller dog). Day 18 to 
day 21: this group of days has 2 categories of what will happen; dogs undergoing CSF taps that 
day or on the following days and dogs having already undergone the CSF tap on a previous day. 
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For the dogs undergoing the CSF tap that day or the following days: up to 3ML of blood will be 
collected at up to 3 time points with 3-4 hours separating the points. The blood total will not 
exceed 6mL (1% of total blood volume of a smaller dog). For dogs having already undergone the 
CSF tap on a previous day: up to 3mL of blood was collected all at once (0.5% of total blood 
volume in a smaller dog) and day 22 up to day 25: up to 3mL of blood was collected at once 
(0.5% of total blood volume in a smaller dog). 
 
 
Table 1: Dog Study Design showcasing what was collected and how much was collected. 
 
Results 
In the mice study, EcNL-LDOPA-Rham-Re increased plasma L-DOPA levels significantly after 
treatment at the 4 and 6 hour time points when compared to the non-treated and Benserizide 
treated control groups. In addition to this, homovanillic acid (HVA), a dopamine metabolite that 
increases when more dopamine is being produced in the brain, was significantly increased in 
the urine at 6 hours post treatment that further proves the increased plasma L-DOPA 
metabolism. In the dog study, fecal scores show that the CFU/g values in Figure 1 are higher 
during the treatment and the washout showing that the treatment was beneficial because of 
the EcNLDOPA4 levels still being up in the washout. This means that the bacteria in the gut is still 
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providing some support to PD after treatment has ended. In addition to the fecal EcNLDOPA4 
quantification, the fecal data shows that the fecal score averages to 2, which means the dogs 
remained healthy throughout the study. The plasma profile of L-DOPA fluctuates slightly 
throughout the trail, but stay in a good range for L-DOPA to be effective. Dopamine levels are 
low throughout the trail with Benserizide levels staying consistent with very little fluctuations. 
In the washout period, there is a spike in L-DOPA and Benserizide plasma levels at the beginning 
of the period, but they go back down within the next time point and trail off for the rest of the 



































Figure 1: Quantification of EcNLDOPA4 by qPCR in Dog feces. All dogs were orally administered EcNLDOPA4 induced with 0.5% 
Rhamnose and Benserazide at a respective doses of 1x1011CFU and 200mg every 12h (q12h). Moderate/fresh fecal samples 
were collected ad libitum,  followed by extraction and quantification by qPCR. Copy number were quantified and normalized to 
fecal weight for respective dogs (n = 5-10) A. Logarithmic values for CFU/g for respective days 
Conclusions 
Overall, the Levodopa treatment increases stability of the LDOPA concentration in the plasma. 
In the mice study, EcN4-LDOPA-Rham-Re increased plasma L-DOPA level significantly after treatment 
compared to the non-treated and Benserazide treated control. For the dog study, L-DOPA levels 
are consistent throughout both trails showing that treatment with the EcN4-LDOPA with 
Benserizide is a good option for keeping L-DOPA levels up during treatment times. This 
treatment of using EcNL bacteria to maintain levels of L-DOPA for treatment might be the next 






Parkinson’s affects millions worldwide and the cost of treatment is only increasing with time. To 
help combat this, researchers are focusing on new ways to catch the disease in early stages of 
life and treat more effectively. The gut-brain axis is one of the new hot topics to improve 
Parkinson’s treatment. In this study, we used a genetically engineered probiotic E. coli called 
EcNL-DOPA, which produces L-DOPA in a sustained manner, while also treating with the gold 
standard treatment of L-DOPA in combination with Benserazide to maximize levodopa’s 
diffusion in the brain. This combination of treatment proved significant in keeping L-DOPA 
plasma levels consistent though both trails showing its potential to be a useful treatment in 
future clinical studies. With the positive results of the studies, there are also limitations that are 
important to state. Due to the small sizes of the samples groups, these studies are not 
comprehensive. Along with small sample sizes, no test were done with the mucosa microbiome. 
The data of the microbiome was taken from the fecal collection with each species of animal and 
feces can only do and show so much about the microbiome. The next step in order to improve 
these limitations is further studies on dogs can be done with more testing on the microbiome in 
addition to larger sample sizes in order to be more comprehensive to give a better idea of these 
effects before moving onto clinical trials in humans. Our prediction is that it will be possible to 
have a good understanding of the outcome of using EcNL-DOPA probiotic in addition to L-DOPA 
with Benserazide treatment and use this understanding to move this treatment on to human 
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